Abstract
Background X - linked agammaglobulinemia (XLA, OMIM #300755) is a primary immunodeficiency disorder caused by pathogenic variations in the BTK gene, characterized by failure of development and maturation of B lymphocytes. The estimated prevalence worldwide is 1 in 190,000 male births. Recently, genome sequencing has been widely used in difficult to diagnose and familial cases. We report a large Indian family suffering from XLA with five affected individuals.
Methods We performed complete blood count, immunoglobulin assay, and lymphocyte subset analysis for all patients and analyzed Btk expression for one patient and his mother. Whole exome sequencing (WES) for four patients, and whole genome sequencing (WGS) for two patients have been performed. Carrier screening was done for 17 family members using Multiplex Ligation-dependent Probe Amplification (MLPA) and haplotype ancestry mapping using fineSTRUCTURE was performed.
Results All patients had hypogammaglobulinemia and low CD19+ B cells. One patient who underwent Btk estimation had low expression and his mother showed a mosaic pattern. On structural variant analysis of WGS data, we found a novel large deletion of 5,296 bp at loci chrX:100,624,323-100,629,619 encompassing exons 3-5 of the BTK gene. Family screening revealed seven carriers for the deletion. Two patients had a successful HSCT. Haplotype mapping revealed mainly South Asian ancestry.
Conclusion Whole genome sequencing led to identification of the accurate genetic mutation which could help in early diagnosis leading to improved outcomes, prevention of permanent organ damage and improved quality of life, as well as enabling prenatal diagnosis.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The work was supported by Council of Scientific and Industrial Research (CSIR) India through grant number MLP1801 (RareGen-CSIR India), Science & Engineering Research Board (SERB) through grant number EMR/2016/006828/HS (SERB, DST) and Foundation for Primary Immunodeficiency Diseases (FPID, USA).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Institutional Ethics Committee (Ethics No. GMCKKD/RP2017/IEC/147).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵# Joint first authors
We have corrected the affiliation of one of the author "Abhinav Jain"
Data Availability
The sequencing data in the study will be provided upon request, as it could be potentially identifiable and contains patient sensitive information. Access to the sequencing data could be requested by mailing to Dr. Jyoti Yadav (j.yadav{at}igib.res.in) who is the convener of the Institutional Human Ethics Committee of CSIR-Institute of Genomics and Integrative Biology. Similarly, the pedigree of the family and descriptive patient clinical information will be provided upon request to the corresponding author Dr. Vinod Scaria (vinods{at}igib.in) Principal Scientist of CSIR-Institute of Genomics and Integrative Biology.
